Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches

Table 2

Demographic and clinical characteristics of the study group, depending on the line of disease-modifying therapy.

Parameters	LI	LII
	44	19	10	—
[]	IF1a//		—	—
	22/17/5	7/12
Age [years]			—	0.11
Age at the beginning of DMT [years]				0.23
Age [% of females]			60.0	0.72
Time of MS [months]			—	0.048
Time of DMT [months]			—	0.005
[score]			—	0.10
[]			—	0.51
T2 lesions (from the time of diagnosis) []			—	0.45
New MRI lesions (within the last year) []			—	0.42
MRI lesions (from the time of diagnosis) []			—	0.60
New Gd+ MRI lesions (within the last year) []			—	0.24

A: disease-modifying therapy; b: Expanded Disability Status Scale; c: annual relapse rate; d: magnetic resonance imaging; e: Gadovist; f: interferon beta; g: glatiramer acetate; h: natalizumab; i: fingolimod; j: control group.